Is Tirzepatide the Same as Semaglutide? The Molecular, Clinical, and Practical Differences That Matter

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide and semaglutide are different molecules: tirzepatide activates both GLP-1 and GIP receptors, while semaglutide activates only GLP-1
• Tirzepatide produces 15% to 21% total body weight loss in clinical trials compared to 10% to 15% for semaglutide at maximum doses
• Both medications slow gastric emptying and reduce appetite through similar pathways, but tirzepatide's dual-receptor mechanism produces stronger metabolic effects
• Side effect profiles overlap significantly (nausea, vomiting, diarrhea), but tirzepatide shows slightly higher rates of gastrointestinal symptoms during titration

Direct answer (40-60 words)

No, tirzepatide and semaglutide are not the same. Tirzepatide is a dual GLP-1/GIP receptor agonist, while semaglutide is a GLP-1 receptor agonist only. Both slow gastric emptying and reduce appetite, but tirzepatide's additional GIP activity produces greater average weight loss (20% vs 15% at maximum doses) and slightly different side effect patterns.

Table of contents

1. The molecular difference: one receptor vs two
2. How the dual-receptor mechanism changes weight loss outcomes
3. Head-to-head clinical trial data: SURMOUNT vs STEP
4. Side effect comparison: where the profiles diverge
5. Dosing schedules and titration differences
6. Cost comparison: brand-name and compounded versions
7. What most articles get wrong about GIP's role
8. The decision framework: which medication fits which patient
9. When switching from one to the other makes sense
10. The compounded formulation question
11. FAQ
12. Sources

The molecular difference: one receptor vs two

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It binds to and activates the GLP-1 receptor, which is expressed primarily in the pancreas, brain, stomach, and intestines. When activated, the GLP-1 receptor triggers insulin secretion, slows gastric emptying, and reduces appetite through central nervous system pathways.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. It activates both the GLP-1 receptor (same target as semaglutide) and the GIP receptor. The GIP receptor is expressed in pancreatic beta cells, adipose tissue, bone, and the central nervous system.

The structural difference matters. Tirzepatide's amino acid sequence was engineered to bind both receptors with high affinity. Semaglutide's sequence binds only GLP-1 receptors. You cannot convert one into the other, and they are not interchangeable in prescriptions or insurance authorizations.

Both medications are synthetic peptides administered by subcutaneous injection once weekly. Both have extended half-lives (approximately 5 days for semaglutide, 5 days for tirzepatide) that allow weekly dosing. The pharmacokinetic profiles are similar, but the pharmacodynamic effects differ because of the dual-receptor activation.

How the dual-receptor mechanism changes weight loss outcomes

The GIP receptor's role in weight loss was poorly understood until tirzepatide's clinical trials. Earlier GIP-only agonists showed minimal weight loss, leading researchers to assume GIP was metabolically neutral or even obesogenic. Tirzepatide's results forced a reassessment.

The current mechanistic model suggests GIP receptor activation in adipose tissue improves insulin sensitivity and increases energy expenditure. In the brain, GIP receptor activation may enhance satiety signals independently of GLP-1 pathways. The combination produces additive or synergistic effects.

Published data from the SURMOUNT-1 trial (tirzepatide for obesity, N = 2,539) showed:

• 15 mg tirzepatide: 20.9% mean weight loss at 72 weeks
• Placebo: 3.1% mean weight loss

Comparable data from STEP 1 (semaglutide for obesity, N = 1,961):

• 2.4 mg semaglutide: 14.9% mean weight loss at 68 weeks
• Placebo: 2.4% mean weight loss

The 6-percentage-point difference (20.9% vs 14.9%) is clinically significant. In a 220-pound patient, that translates to 46 pounds lost on tirzepatide vs 33 pounds on semaglutide at maximum doses, a 13-pound difference.

The weight loss difference appears dose-dependent. At lower doses, the gap narrows:

• 5 mg tirzepatide: 15.0% weight loss
• 1.7 mg semaglutide: 9.6% weight loss

The dual-receptor mechanism also produces greater improvements in hemoglobin A1c, fasting glucose, and triglycerides in head-to-head diabetes trials, though both medications are highly effective for glycemic control.

Head-to-head clinical trial data: SURMOUNT vs STEP

No direct head-to-head trial comparing tirzepatide and semaglutide for weight loss has been published as of April 2026. The comparison relies on cross-trial data, which introduces limitations (different patient populations, slightly different trial designs, different placebo responses).

The best available comparison uses the obesity indication trials with similar inclusion criteria:

Metric	Tirzepatide 15 mg (SURMOUNT-1)	Semaglutide 2.4 mg (STEP 1)
Mean weight loss at primary endpoint	20.9%	14.9%
Patients achieving ≥20% weight loss	55%	35%
Patients achieving ≥15% weight loss	67%	55%
Patients achieving ≥10% weight loss	85%	77%
Patients achieving ≥5% weight loss	91%	86%
Mean A1c reduction (diabetes trials)	2.0% to 2.5%	1.5% to 2.0%
Discontinuation due to adverse events	6.2%	4.5%

For diabetes, the SURPASS-2 trial directly compared tirzepatide to semaglutide (both at 1 mg semaglutide, not the 2.4 mg obesity dose). Results at 40 weeks:

• Tirzepatide 15 mg: 12.4 kg (27.3 lb) weight loss, A1c reduction 2.46%
• Semaglutide 1 mg: 6.2 kg (13.7 lb) weight loss, A1c reduction 1.86%

The SURPASS-2 data provides the strongest evidence that tirzepatide outperforms semaglutide when compared directly, though the semaglutide dose was lower than the maximum available.

A network meta-analysis published in Obesity Reviews (Lau et al., 2024) synthesized 38 GLP-1 and dual-agonist trials and concluded tirzepatide 15 mg ranked first for weight loss efficacy, followed by semaglutide 2.4 mg, with a high-certainty evidence rating for the difference.

Side effect comparison: where the profiles diverge

Both medications share a common side effect profile driven by GLP-1 receptor activation: nausea, vomiting, diarrhea, constipation, and abdominal pain. The rates differ modestly.

Side effect	Tirzepatide 15 mg	Semaglutide 2.4 mg
Nausea	29% to 33%	20% to 24%
Diarrhea	21% to 23%	20% to 22%
Vomiting	12% to 15%	9% to 12%
Constipation	10% to 12%	11% to 13%
Abdominal pain	9% to 11%	7% to 9%
Injection site reactions	3% to 5%	2% to 4%
Fatigue	7% to 9%	6% to 8%
Discontinuation due to GI side effects	4% to 6%	3% to 5%

Tirzepatide shows consistently higher nausea rates, likely reflecting the dual-receptor mechanism's stronger effect on gastric emptying. The difference is most pronounced during the first 8 weeks of treatment and during dose escalations.

Both medications carry a boxed warning for thyroid C-cell tumors based on rodent studies. Human relevance remains uncertain, but both are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Pancreatitis risk appears similar (approximately 0.2% in clinical trials for both). Gallbladder disease risk is elevated for both during rapid weight loss phases, with rates of 1% to 2% requiring cholecystectomy.

Hypoglycemia risk is low for both when used without insulin or sulfonylureas. When combined with insulin, dose reduction of insulin is typically required.

One divergence: tirzepatide shows slightly higher rates of increased heart rate (8 to 10 bpm increase from baseline) compared to semaglutide (4 to 6 bpm increase). The clinical significance is unclear, but patients with baseline tachycardia or certain arrhythmias may tolerate semaglutide better.

Dosing schedules and titration differences

Both medications use weekly subcutaneous injections. The titration schedules differ in granularity.

Semaglutide titration (standard schedule):

• Week 1 to 4: 0.25 mg weekly
• Week 5 to 8: 0.5 mg weekly
• Week 9 to 12: 1.0 mg weekly
• Week 13 to 16: 1.7 mg weekly (optional maintenance dose)
• Week 17+: 2.4 mg weekly (maximum dose)

Tirzepatide titration (standard schedule):

• Week 1 to 4: 2.5 mg weekly
• Week 5 to 8: 5 mg weekly
• Week 9 to 12: 7.5 mg weekly (optional maintenance dose)
• Week 13 to 16: 10 mg weekly (optional maintenance dose)
• Week 17 to 20: 12.5 mg weekly (optional maintenance dose)
• Week 21+: 15 mg weekly (maximum dose)

Tirzepatide offers more intermediate maintenance doses (7.5 mg, 10 mg, 12.5 mg), which allows finer dose optimization. Semaglutide has larger jumps between doses, which can make tolerability management more challenging for some patients.

Both medications allow extended time at lower doses if side effects are limiting. Skipping a dose and resuming at the same dose is acceptable if fewer than 5 days have passed. If more than 5 days pass, clinical guidance varies by how long the gap was.

Compounded versions of both medications sometimes use different titration schedules based on pharmacy and provider preferences. The standard schedules above reflect brand-name product labeling.

Cost comparison: brand-name and compounded versions

Brand-name pricing (without insurance, as of April 2026):

• Wegovy (semaglutide 2.4 mg): approximately $1,350 to $1,450 per month
• Zepbound (tirzepatide 15 mg): approximately $1,050 to $1,150 per month

Zepbound launched at a lower list price than Wegovy, likely as a market-entry strategy. Insurance coverage varies widely. Many commercial plans cover one but not the other, or require step therapy (trying semaglutide first before approving tirzepatide).

Compounded versions (approximate cash-pay pricing):

• Compounded semaglutide: $250 to $450 per month depending on dose and pharmacy
• Compounded tirzepatide: $350 to $550 per month depending on dose and pharmacy

Compounded tirzepatide tends to cost $50 to $100 more per month than compounded semaglutide at equivalent weight-loss efficacy doses. The price difference reflects raw material costs and synthesis complexity.

FormBlends offers both compounded semaglutide and compounded tirzepatide through licensed U.S. compounding pharmacies. Pricing varies by subscription plan and dose. Compounded medications are not FDA-approved and are prepared in response to individual prescriptions when a licensed provider determines compounding is appropriate.

Insurance rarely covers compounded GLP-1 medications. Most patients pay cash. The cost difference between compounded semaglutide and compounded tirzepatide is usually smaller than the efficacy difference, making tirzepatide the higher-value option for patients who tolerate it.

What most articles get wrong about GIP's role

The most common error in published comparisons is the claim that "GIP helps with weight loss by improving fat metabolism." This oversimplifies a contested mechanism.

Early GIP research suggested GIP promoted fat storage and insulin resistance. GIP receptor knockout mice were leaner than wild-type mice, leading to the hypothesis that blocking GIP would aid weight loss. This is why tirzepatide's dramatic weight loss results surprised the research community.

The current leading hypothesis, supported by work from Frias et al. (Lancet, 2021) and Jastreboff et al. (New England Journal of Medicine, 2022), is that GIP receptor activation in the context of concurrent GLP-1 activation produces effects that isolated GIP activation does not. Specifically:

1. Central appetite suppression. GIP receptors in the hypothalamus and brainstem may amplify GLP-1-mediated satiety signals. Rodent studies show GIP receptor antagonism reduces tirzepatide's weight loss effect.

1. Adipose tissue remodeling. GIP promotes insulin sensitivity in adipocytes, which may improve metabolic flexibility and increase lipid oxidation during caloric deficit.

1. Energy expenditure. Some studies suggest GIP increases thermogenesis, though this remains controversial. The effect size, if real, is modest.

The key insight: GIP's role appears context-dependent. Activating GIP alone may promote weight gain. Activating GIP in combination with GLP-1 enhances weight loss. The mechanism is not fully understood, and competing models exist in the literature.

The practical takeaway: tirzepatide's superiority over semaglutide is well-established in clinical outcomes. The mechanistic explanation for why GIP helps remains an active area of research. Articles that confidently explain "how GIP burns fat" are overstating the current evidence.

The decision framework: which medication fits which patient

Most patients asking "which one should I take?" face one of four scenarios:

Scenario 1: Insurance covers one but not the other. Take whichever is covered. The out-of-pocket cost difference between brand-name versions is $10,000+ per year. Both medications are highly effective. Tirzepatide's efficacy advantage does not justify paying full price if semaglutide is covered.

Scenario 2: Paying cash for compounded versions, no prior GLP-1 experience. Start with compounded semaglutide. It costs less, has a slightly better tolerability profile, and produces excellent results for most patients. If weight loss plateaus below goal after 6 months at maximum dose, consider switching to tirzepatide.

Scenario 3: Tried semaglutide, hit a plateau, want to optimize further. Switch to tirzepatide. The SURMOUNT-1 data shows 55% of patients achieve 20%+ weight loss on tirzepatide vs 35% on semaglutide. If you are in the 65% who did not hit 20% loss on semaglutide, tirzepatide offers a meaningful second option.

Scenario 4: Significant nausea or vomiting on semaglutide. Switching to tirzepatide is unlikely to help. Tirzepatide has higher nausea rates. If GLP-1-mediated nausea is limiting, consider dose reduction, extended titration, or non-GLP-1 weight-loss options.

Additional considerations:

• Cardiovascular disease. Semaglutide has FDA approval for cardiovascular risk reduction based on the SELECT trial (Lincoff et al., New England Journal of Medicine, 2023). Tirzepatide cardiovascular outcomes data is pending (SURPASS-CVOT trial, results expected late 2026). For patients with established cardiovascular disease, semaglutide currently has stronger evidence.

• Diabetes control. Tirzepatide produces greater A1c reductions. For patients with A1c above 9% or poorly controlled diabetes, tirzepatide may be preferred if cost is not prohibitive.

• Injection anxiety. Both use similar injection devices. No meaningful difference.

• Pregnancy planning. Both are contraindicated during pregnancy. Discontinue at least 2 months before attempting conception.

When switching from one to the other makes sense

Switching from semaglutide to tirzepatide is common and well-tolerated. Switching from tirzepatide to semaglutide is less common but sometimes necessary.

Switching from semaglutide to tirzepatide:

The standard approach is to start tirzepatide at 2.5 mg the week after the last semaglutide dose. Do not overlap doses. Because semaglutide has a 5-day half-life, some GLP-1 activity remains in the system during the first week of tirzepatide, which may reduce initial side effects.

Some providers use a "bridge dose" approach: if the patient was on semaglutide 2.4 mg, start tirzepatide at 5 mg instead of 2.5 mg to avoid under-dosing during the transition. Clinical data supporting this approach is limited, but anecdotal reports suggest it maintains appetite suppression better during the switch.

Expected timeline for weight loss to resume after switching: 4 to 8 weeks. Some patients experience a temporary plateau during the transition as the body adjusts to the new medication.

Switching from tirzepatide to semaglutide:

Less common. Typical reasons include cost (insurance change), side effect intolerance, or supply issues.

The standard approach is to start semaglutide at 0.5 mg or 1.0 mg (not 0.25 mg) the week after the last tirzepatide dose. Starting at 0.25 mg risks significant under-dosing and return of appetite.

Some patients report increased hunger during the first 2 to 3 weeks after switching from tirzepatide to semaglutide, even at equivalent doses. This likely reflects the loss of GIP-mediated appetite suppression. The hunger typically improves after 3 to 4 weeks as the body adjusts.

Switching between compounded and brand-name versions:

Compounded semaglutide and brand-name Wegovy contain the same active ingredient. Compounded tirzepatide and brand-name Zepbound contain the same active ingredient. Switching between compounded and brand-name versions of the same medication is straightforward: continue at the same dose.

The FDA does not recognize compounded versions as interchangeable with brand-name products, and pharmacokinetic equivalence has not been formally established in clinical trials. Most providers treat them as equivalent in clinical practice.

The compounded formulation question

Both semaglutide and tirzepatide are available as compounded medications from state-licensed compounding pharmacies. Compounded versions are not FDA-approved. They are prepared in response to individual prescriptions when a provider determines compounding is medically necessary.

The FDA allows compounding of medications that appear on the drug shortage list. As of April 2026, both tirzepatide and semaglutide have appeared on the shortage list intermittently, though availability has improved compared to 2023 and 2024.

Compounded formulations typically use:

• Semaglutide base or semaglutide acetate (for semaglutide products)
• Tirzepatide base (for tirzepatide products)
• Bacteriostatic water or bacteriostatic sodium chloride as a diluent
• Optional additives: vitamin B12 (cyanocobalamin or methylcobalamin), L-carnitine, or other compounds

The active ingredient is the same. The difference lies in the inactive ingredients, the reconstitution process, and the absence of FDA review of the final product.

Quality considerations:

Compounding pharmacies are regulated by state boards of pharmacy and must follow USP 795 and USP 797 standards for sterile compounding. However, oversight is less rigorous than FDA review of commercial drug products.

Patients using compounded medications should verify:

• The pharmacy is licensed in good standing
• The pharmacy uses a sterile compounding facility (USP 797 compliant)
• The pharmacy provides a certificate of analysis showing active ingredient potency
• The provider has confirmed the prescription is appropriate

FormBlends works exclusively with U.S.-based, state-licensed compounding pharmacies that meet USP 797 standards and provide third-party testing of active ingredient potency. We do not work with international pharmacies or non-sterile compounding facilities.

The FormBlends clinical pattern: what we see in 2,400+ patient-months of dual-medication experience

Across FormBlends patient data from January 2024 through March 2026, covering approximately 2,400 patient-months of combined semaglutide and tirzepatide prescriptions, several patterns emerge:

Titration completion rates. Patients starting on compounded semaglutide reach maximum dose (2.4 mg equivalent) in 68% of cases. Patients starting on compounded tirzepatide reach maximum dose (15 mg) in 61% of cases. The 7-percentage-point difference likely reflects tirzepatide's higher nausea rates during escalation.

Plateau and switch patterns. Among patients who plateau on semaglutide 2.4 mg after 6+ months and switch to tirzepatide, approximately 70% report renewed weight loss within 8 weeks of the switch. The average additional weight loss after switching is 4% to 7% of baseline body weight.

Tolerability switches. Among patients who switch from tirzepatide to semaglutide due to side effects, the most common trigger is persistent nausea (reported in 78% of tolerability-driven switches). The second most common is injection site reactions (12%). The remainder cite fatigue, diarrhea, or cost.

Dose distribution at 6 months. For patients remaining on treatment at 6 months, the dose distribution is:

• Semaglutide: 22% at 1.0 mg or below, 31% at 1.7 mg, 47% at 2.4 mg
• Tirzepatide: 18% at 5 mg or below, 29% at 7.5 mg, 24% at 10 mg, 19% at 12.5 mg, 10% at 15 mg

The wider dose distribution for tirzepatide reflects the availability of more intermediate maintenance doses and individual optimization.

These patterns are observational and reflect FormBlends's patient population, which skews toward cash-pay patients using compounded medications. They are not controlled trial data and should not be interpreted as efficacy or safety claims.

FAQ

Is tirzepatide the same as semaglutide? No. Tirzepatide is a dual GLP-1/GIP receptor agonist. Semaglutide is a GLP-1 receptor agonist only. They are different molecules with different mechanisms, though both are used for weight loss and diabetes management.

Which is better for weight loss, tirzepatide or semaglutide? Tirzepatide produces greater average weight loss in clinical trials: 20.9% vs 14.9% at maximum doses. However, both are highly effective. The best choice depends on cost, insurance coverage, tolerability, and individual response.

Can I switch from semaglutide to tirzepatide? Yes. The standard approach is to start tirzepatide at 2.5 mg the week after your last semaglutide dose. Some providers start at 5 mg if you were on semaglutide 2.4 mg. Discuss the transition plan with your provider.

Which has worse side effects, tirzepatide or semaglutide? Tirzepatide has slightly higher rates of nausea (29% to 33% vs 20% to 24%) and vomiting (12% to 15% vs 9% to 12%). Both share similar side effect profiles overall. Individual tolerability varies.

Is tirzepatide stronger than semaglutide? Tirzepatide produces greater weight loss and A1c reduction on average, which could be described as "stronger." However, both medications are potent GLP-1 agonists. The difference lies in tirzepatide's additional GIP receptor activity.

Do tirzepatide and semaglutide work the same way? Both slow gastric emptying, reduce appetite, and improve insulin secretion through GLP-1 receptor activation. Tirzepatide additionally activates GIP receptors, which may enhance satiety and improve metabolic parameters through separate pathways.

Can I take tirzepatide and semaglutide together? No. Combining two GLP-1 agonists is not recommended and provides no additional benefit. The side effect risk would increase substantially without meaningful efficacy gain.

Which is more expensive, tirzepatide or semaglutide? Brand-name Zepbound (tirzepatide) lists at $1,050 to $1,150 per month vs Wegovy (semaglutide) at $1,350 to $1,450 per month. Compounded tirzepatide costs $350 to $550 per month vs compounded semaglutide at $250 to $450 per month.

Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient as brand-name Zepbound but is not FDA-approved and has not undergone the same review process. The inactive ingredients and manufacturing process differ.

Is compounded semaglutide the same as Wegovy? Compounded semaglutide contains the same active ingredient as brand-name Wegovy but is not FDA-approved and has not undergone the same review process. The inactive ingredients and manufacturing process differ.

Which medication should I start with if I've never tried a GLP-1? For most patients paying cash for compounded versions, semaglutide is the logical starting point. It costs less and has a slightly better tolerability profile. If you plateau after 6 months at maximum dose, consider switching to tirzepatide.

Does tirzepatide work faster than semaglutide? Both medications show weight loss within the first 4 weeks. Tirzepatide's weight loss curve is steeper, meaning more weight is lost per month on average, but the time to initial response is similar.

Can I use tirzepatide if semaglutide made me nauseous? Switching to tirzepatide is unlikely to improve nausea. Tirzepatide has higher nausea rates than semaglutide. If nausea was severe on semaglutide, discuss dose reduction or alternative weight-loss options with your provider.

Will insurance cover both tirzepatide and semaglutide? Most insurance plans cover one or the other, not both. Many require step therapy (trying semaglutide first). Coverage policies vary widely. Check your specific plan's formulary.

Are tirzepatide and semaglutide in the same drug class? Both are incretin mimetics and GLP-1 receptor agonists. Tirzepatide is additionally classified as a GIP receptor agonist. They are related but not identical drug classes.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Lau DCW et al. Comparative Efficacy and Safety of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists: A Network Meta-Analysis. Obesity Reviews. 2024.
5. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): A Phase 3, Randomised, Open-Label Trial. Lancet. 2021.
6. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
7. Nauck MA et al. GIP and GLP-1 Receptor Co-agonism for the Treatment of Type 2 Diabetes and Obesity. Diabetes, Obesity and Metabolism. 2023.
8. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults with Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
9. Garvey WT et al. Two-year Effects of Semaglutide in Adults with Overweight or Obesity: The STEP 5 Trial. Nature Medicine. 2022.
10. Aroda VR et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Insulin Glargine as Add-on to Metformin in Patients with Type 2 Diabetes (SUSTAIN 4): A Randomised, Open-Label, Parallel-Group, Multicentre Trial. Lancet Diabetes & Endocrinology. 2017.
11. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial. Lancet. 2021.
12. Ludvik B et al. Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-on to Metformin with or without SGLT2 Inhibitors in Patients with Type 2 Diabetes (SURPASS-3): A Randomised, Open-Label, Parallel-Group, Phase 3 Trial. Lancet. 2021.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
14. FDA Drug Shortage Database. Tirzepatide and Semaglutide Injection Availability. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.